Mitigating the economic and health challenges of COVID-19 is hindered by the absence of mass population testing. Available platforms are designed for lab-use and rely on sophisticated technologies and readers. They are slow, expensive, hard to manufacture and overload healthcare professionals with time consuming manual workflows; presenting massive obstacles to high throughput testing. We introduce a novel platform to diagnose COVID-19, which includes a digital test that combines fluorescent lateral flow assays with our patent-pending cost-optimized lateral flow test platform which was initially developed to detect H1N1. We have formed the essential alliances with key partners to rapidly scale up manufacturing and distribution to the points-of-need. Nasal swabs (and soon saliva samples) are tested in under 15 minutes. The digital results are wirelessly communicated to the participants’ mobile devices and the cloud thereby providing healthcare providers with test status and sharing real-time analytics and monitoring capabilities with health authorities. In the first stage, the test will be deployed into CLIA-waived point-of-care clinics, walk-in facilities and drive-thru testing centers for less than $35 for the digital test and with an effective cost of less than $10 per disposable test. After full validation, we will immediately extend deployment to at-home use by leveraging machine vision-guided self-testing. By combining IoT technologies that are proven to enable large-scale production with rapid diagnostic testing we believe we are uniquely positioned to increase testing throughput by 10X-100X. RADx re-enforcement will propel the launch of the system in highly condensed timeframes to meet the enormous need.